

World Journal of *Clinical Cases*

World J Clin Cases 2022 November 16; 10(32): 11665-12065



Contents

Thrice Monthly Volume 10 Number 32 November 16, 2022

OPINION REVIEW

- 11665** Combined use of lactoferrin and vitamin D as a preventive and therapeutic supplement for SARS-CoV-2 infection: Current evidence

Cipriano M, Ruberti E, Tovani-Palone MR

REVIEW

- 11671** Role of adherent invasive *Escherichia coli* in pathogenesis of inflammatory bowel disease
- Zheng L, Duan SL, Dai YC, Wu SC*
- 11690** Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment

Huang ML, Shen GT, Li NL

MINIREVIEWS

- 11702** Overlap of diabetic ketoacidosis and hyperosmolar hyperglycemic state
- Hassan EM, Mushtaq H, Mahmoud EE, Chhibber S, Saleem S, Issa A, Nitesh J, Jama AB, Khedr A, Boike S, Mir M, Attallah N, Surani S, Khan SA*

ORIGINAL ARTICLE

Case Control Study

- 11712** Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation
- Hu SL, Liu M, Zhang JY*

Retrospective Cohort Study

- 11726** Development and validation of novel nomograms to predict survival of patients with tongue squamous cell carcinoma
- Luo XY, Zhang YM, Zhu RQ, Yang SS, Zhou LF, Zhu HY*

Retrospective Study

- 11743** Non-invasive model for predicting esophageal varices based on liver and spleen volume
- Yang LB, Zhao G, Tantai XX, Xiao CL, Qin SW, Dong L, Chang DY, Jia Y, Li H*

Clinical Trials Study

- 11753** Clinical efficacy of electromagnetic field therapy combined with traditional Chinese pain-reducing paste in myofascial pain syndrome
- Xiao J, Cao BY, Xie Z, Ji YX, Zhao XL, Yang HJ, Zhuang W, Sun HH, Liang WM*

- 11766** Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4

Xu L, Lu LL, Wang YT, Zhou JB, Wang CX, Xin JD, Gao JD

Observational Study

- 11775** Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Wang YF, Wang TY, Liao TT, Lin MH, Huang TH, Hsieh MC, Chen VCH, Lee LW, Huang WS, Chen CY

- 11789** Development and validation of a risk assessment model for prediabetes in China national diabetes survey

Yu LP, Dong F, Li YZ, Yang WY, Wu SN, Shan ZY, Teng WP, Zhang B

Case Control Study

- 11804** T-cell immunoglobulin mucin molecule-3, transformation growth factor β , and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma

Wu H, Sun HC, Ouyang GF

META-ANALYSIS

- 11812** Prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: A systematic review and meta-analysis

Wang XY, Chai YM, Huang WH, Zhang Y

CASE REPORT

- 11827** Paraneoplastic neurological syndrome caused by cystitis glandularis: A case report and literature review

Zhao DH, Li QJ

- 11835** Neck pain and absence of cranial nerve symptom are clues of cervical myelopathy mimicking stroke: Two case reports

Zhou LL, Zhu SG, Fang Y, Huang SS, Huang JF, Hu ZD, Chen JY, Zhang X, Wang JY

- 11845** Nine-year survival of a 60-year-old woman with locally advanced pancreatic cancer under repeated open approach radiofrequency ablation: A case report

Zhang JY, Ding JM, Zhou Y, Jing X

- 11853** Laparoscopic treatment of inflammatory myofibroblastic tumor in liver: A case report

Li YY, Zang JF, Zhang C

- 11861** Survival of a patient who received extracorporeal membrane oxygenation due to postoperative myocardial infarction: A case report

Wang QQ, Jiang Y, Zhu JG, Zhang LW, Tong HJ, Shen P

- 11869** Triple hit to the kidney-dual pathological crescentic glomerulonephritis and diffuse proliferative immune complex-mediated glomerulonephritis: A case report

Ibrahim D, Brodsky SV, Satoskar AA, Biederman L, Maroz N

- 11877** Successful transcatheter arterial embolization treatment for chest wall haematoma following permanent pacemaker implantation: A case report
Zheng J, Tu XM, Gao ZY
- 11882** Brachiocephalic to left brachial vein thrombotic vasculitis accompanying mediastinal pancreatic fistula: A case report
Kokubo R, Yunaiyama D, Tajima Y, Kugai N, Okubo M, Saito K, Tsuchiya T, Itoi T
- 11889** Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature
He MY, Yan FF, Cen KL, Shen P
- 11898** Successful treatment of pulmonary hypertension in a neonate with bronchopulmonary dysplasia: A case report and literature review
Li J, Zhao J, Yang XY, Shi J, Liu HT
- 11908** Idiopathic tenosynovitis of the wrist with multiple rice bodies: A case report and review of literature
Tian Y, Zhou HB, Yi K, Wang KJ
- 11921** Endoscopic resection of bronchial mucoepidermoid carcinoma in a young adult man: A case report and review of literature
Ding YM, Wang Q
- 11929** Blue rubber bleb nevus syndrome complicated with disseminated intravascular coagulation and intestinal obstruction: A case report
Zhai JH, Li SX, Jin G, Zhang YY, Zhong WL, Chai YF, Wang BM
- 11936** Management of symptomatic cervical facet cyst with cervical interlaminar epidural block: A case report
Hwang SM, Lee MK, Kim S
- 11942** Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report
Liu XH, Zou QM, Cao JD, Wang ZC
- 11949** Successful live birth following hysteroscopic adhesiolysis under laparoscopic observation for Asherman's syndrome: A case report
Kakinuma T, Kakinuma K, Matsuda Y, Ohwada M, Yanagida K
- 11955** What is responsible for acute myocardial infarction in combination with aplastic anemia? A case report and literature review
Zhao YN, Chen WW, Yan XY, Liu K, Liu GH, Yang P
- 11967** Repeated ventricular bigeminy by trigeminocardiac reflex despite atropine administration during superficial upper lip surgery: A case report
Cho SY, Jang BH, Jeon HJ, Kim DJ
- 11974** Testis and epididymis-unusual sites of metastatic gastric cancer: A case report and review of the literature
Ji JJ, Guan FJ, Yao Y, Sun LJ, Zhang GM

- 11980** t(4;11) translocation in hyperdiploid *de novo* adult acute myeloid leukemia: A case report
Zhang MY, Zhao Y, Zhang JH
- 11987** Sun-burn induced upper limb lymphedema 11 years following breast cancer surgery: A case report
Li M, Guo J, Zhao R, Gao JN, Li M, Wang LY
- 11993** Minimal change disease caused by polycythemia vera: A case report
Xu L, Lu LL, Gao JD
- 12000** Vitreous amyloidosis caused by a Lys55Asn variant in transthyretin: A case report
Tan Y, Tao Y, Sheng YJ, Zhang CM
- 12007** Endoscopic nasal surgery for mucocoele and pyogenic mucocoele of turbinate: Three case reports
Sun SJ, Chen AP, Wan YZ, Ji HZ
- 12015** Transcatheter arterial embolization for traumatic injury to the pharyngeal branch of the ascending pharyngeal artery: Two case reports
Yunaiyama D, Takara Y, Kobayashi T, Muraki M, Tanaka T, Okubo M, Saguchi T, Nakai M, Saito K, Tsukahara K, Ishii Y, Homma H
- 12022** Retroperitoneal leiomyoma located in the broad ligament: A case report
Zhang XS, Lin SZ, Liu YJ, Zhou L, Chen QD, Wang WQ, Li JY
- 12028** Primary testicular neuroendocrine tumor with liver lymph node metastasis: A case report and review of the literature
Xiao T, Luo LH, Guo LF, Wang LQ, Feng L
- 12036** Endodontic treatment of the maxillary first molar with palatal canal variations: A case report and review of literature
Chen K, Ran X, Wang Y
- 12045** Langerhans cell histiocytosis involving only the thymus in an adult: A case report
Li YF, Han SH, Qie P, Yin QF, Wang HE

LETTER TO THE EDITOR

- 12052** Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
Triposkiadis F, Giamouzis G, Skoularigis J, Xanthopoulos A
- 12056** Insight into appropriate medication prescribing for elderly in the COVID-19 era
Omar AS, Kaddoura R
- 12059** Commentary on "Gallstone associated celiac trunk thromboembolisms complicated with splenic infarction: A case report"
Tokur O, Aydın S, Kantarci M
- 12062** Omicron targets upper airways in pediatrics, elderly and unvaccinated population
Nori W, Ghani Zghair MA

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Camelia Cristina Diaconu, FACC, FACP, FESC, MHSc, PhD, Associate Professor, Department of Internal Medicine, "Carol Davila" University of Medicine and Pharmacy, Clinical Emergency Hospital of Bucharest, Bucharest 014461, Romania. drcameliadiaconu@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

November 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Heart failure with preserved ejection fraction: A distinct heart failure phenotype?

Filippos Triposkiadis, Grigorios Giamouzis, John Skoularigis, Andrew Xanthopoulos

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Feng R, China; Leslie SJ, United Kingdom

Received: July 20, 2022

Peer-review started: July 20, 2022

First decision: September 5, 2022

Revised: September 15, 2022

Accepted: October 13, 2022

Article in press: October 13, 2022

Published online: November 16, 2022



Filippos Triposkiadis, Grigorios Giamouzis, John Skoularigis, Andrew Xanthopoulos, Department of Cardiology, University Hospital of Larissa, Larissa 41110, Greece

Corresponding author: Andrew Xanthopoulos, FACC, MD, PhD, Senior Postdoctoral Fellow, Department of Cardiology, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. andrewvxanth@gmail.com

Abstract

The present work discusses the serious confusion resulting from the arbitrary nomenclature of heart failure with preserved ejection fraction (HFpEF), the presumed underlying pathophysiology, and the supposed features. A consequence of this misconception is that HFpEF trials have recruited patients with entirely different characteristics rendering the extrapolation of the results of one study to the other infeasible and dramatically affecting diagnosis and treatment.

Key Words: Heart failure; Preserved; Nomenclature; Left ventricular ejection fraction; Pathophysiology; Phenotypic persistence

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Heart failure (HF) with preserved left ventricular ejection fraction heart failure with preserved ejection fraction (HFpEF) raises serious confusion resulting from the arbitrary nomenclature, the presumed underlying pathophysiology, and the supposed features, all of which dramatically impact patient management. HFpEF predominantly represents a group of distinct diseases and not a specific HF phenotype which exhibits phenotypic heterogeneity.


Citation: Triposkiadis F, Giamouzis G, Skoularigis J, Xanthopoulos A. Heart failure with preserved ejection fraction: A distinct heart failure phenotype? *World J Clin Cases* 2022; 10(32): 12052-12055

URL: <https://www.wjgnet.com/2307-8960/full/v10/i32/12052.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i32.12052>

TO THE EDITOR

Heart failure with preserved ejection fraction (HFpEF) [heart failure (HF) with preserved left ventricular ejection fraction (LVEF)] has been defined as HF in the presence of LVEF usually > 40%-55%. However, this HF type raises serious confusion resulting from the arbitrary nomenclature, the presumed underlying pathophysiology, and the supposed features, all of which dramatically impact patient management[1]. The nomenclature HFpEF is inappropriate as several recent studies have shown that the hazard ratios for mortality during follow-up have a U-shaped relationship for echocardiographically determined LVEF with a nadir of risk at a LVEF of 60%–65% regardless of the presence or absence of HF [2]. As a result, HF with a “supernormal” LVEF has been proposed and a HF patient with a LVEF of 45% or 50% has an abnormal and not a “preserved” LVEF. HFpEF has been attributed to a systemic proinflammatory state induced by comorbidities, including overweight/obesity, diabetes mellitus, chronic obstructive pulmonary disease, and salt-sensitive hypertension[3]. A major drawback of this conjecture, which has proved disappointing in HFpEF management, is that the relative independent contribution of the individual comorbidities to the inflammatory state, which characterizes HFpEF, has never been considered. HF is a heterogeneous syndrome in which functional and structural parameters change dynamically during disease progression in a patient-specific fashion. Therefore, HF can be regarded as a spectrum of phenotypes. Each HF phenotype is the result of a patient-specific trajectory wherein the heart remodels towards concentric hypertrophy (*i.e.* HFpEF), eccentric hypertrophy (*i.e.* HF with reduced LVEF), or a combination of both. The way of entry and the subsequent path of the trajectory depend on the patient’s risk factors, comorbidities, and disease modifiers[4,5]. Likewise, there are uncertainties regarding the widely adopted foundational features of HFpEF such as phenotypic persistence and phenotypic heterogeneity. Phenotypic persistence, which denotes the lack of significant changes in LVEF over time, is a prerequisite for establishing HFpEF as a distinct LVEF based HF phenotype[6]. However, several recent studies have demolished this conjecture. It is, therefore, not surprising that the 2022 American College of Cardiology/American Heart Association HF guidelines recommend the serial assessment and reclassification of HF trajectories based on the LVEF, ejecting the “phenotypic persistence” dogma from the frame[7]. Phenotypic heterogeneity is usually present in genetic diseases and describes the fact that even within the same family where all affected individuals share the same mutation, phenotypic variation is prominent, with variable penetrance and expressivity, presenting different degrees of involvement. A typical example is familial hypertrophic cardiomyopathy, one of the HFpEF causes, in which members of the same family may exhibit different patterns and/or severity of LV hypertrophy. In addition, phenotypic heterogeneity often occurs and in complex diseases, like coronary artery disease (CAD). In CAD a spectrum of phenotypes is observed related among others to disease onset and stability (*e.g.*, acute, or stable, recent onset or chronic, fatal, or not), extent of coronary lesions (*e.g.*, number of vessels involved, plaque composition and burden) and the severity of LV structural and functional abnormalities (*e.g.*, presence of LV dysfunction or lack thereof) [8,9]. Unfortunately, the term phenotypic heterogeneity has been erroneously used in HFpEF to denote the inclusion under the HFpEF umbrella of several distinct disease entities such as hypertension, valvular heart disease, hypertrophic cardiomyopathy, and amyloidosis. A consequence of this misconception is that HFpEF trials have recruited patients with entirely different characteristics rendering the extrapolation of the results of one study to the other infeasible and dramatically affecting diagnosis and treatment. For example, it would be irrational to extrapolate the findings of the recently published Empagliflozin Outcome Trial in Patients With Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved Trial)[10], which reported a benefit with Empagliflozin (compared with placebo) in hypertensive HFpEF (hypertension present in more than 90% of participants), to the HFpEF patients enrolled in other studies many of whom suffered from valvular heart disease or hypertrophic cardiomyopathy[6]. It has been suggested that in the realm where machine learning (ML) algorithms may aid in our understanding of phenotypically heterogeneous diseases, HFpEF may be an ideal domain in which to apply ML. ML is based on neural networks which are series of nodes or artificial neurons that are processing elements forming a series of hidden layers. Within each node there is a set of inputs, weight, and a bias value. As an input enters the node, it gets multiplied by a weight value and the resulting output is either observed or passed to the next layer in the neural network. In other words, weight is the parameter within a neural network that transforms input data within the network's hidden layers. Recent studies have reported the promising role of ML for the identification of HFpEF as well as its distinct phenotypic subgroups[11-13]. Nevertheless, further research is needed to establish these findings in larger cohorts. In summary, HFpEF predominantly represents a group of distinct diseases and not a specific HF phenotype which exhibits phenotypic heterogeneity. Moreover, even in patients with the same underlying cause (*e.g.*, hypertension) the “preserved” LVEF may drop significantly adversely affecting prognosis and necessitating treatment changes. It is obvious that in these cases HFpEF merely represents a disease stage (*e.g.*, a stage of hypertensive HF). Whether a conglomerate of diseases or a disease stage, the continuing use of HFpEF as a distinct HF phenotype leads HF research and management to a dead end (Figure 1).



DOI: 10.12998/wjcc.v10.i32.12052 Copyright ©The Author(s) 2022.

Figure 1 It is irrational to believe that the management of a group of diseases covered under the term heart failure with preserved ejection fraction should be based on a single biomarker, namely the left ventricular ejection fraction, as the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction implies. It is noteworthy, that like all trials which demonstrated a potential benefit with medical treatment in heart failure with preserved ejection fraction, more than 90% of the patients in Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction were hypertensive and, in contrast to other HFpEF trials, patients with valvular heart disease or hypertrophic cardiomyopathy were not included suggesting a selection bias. LV: Left ventricular; CPX: Cardiopulmonary exercise testing; 6MW: 6 min walk test; LVER: Left ventricular ejection fraction; HFpEF: Heart failure with preserved ejection fraction.

FOOTNOTES

Author contributions: Triposkiadis F and Xanthopoulos A wrote the letter; Giamouzis G and Skoularigis J revised the letter, and all authors made substantial contributions to conception and design of the study, acquisition of data, or analysis and interpretation of data; drafted the article or made critical revisions related to important intellectual content of the manuscript; and gave final approval of the version of the article to be published.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Greece

ORCID number: Filippou Triposkiadis 0000-0001-6433-4016; Grigorios Giamouzis 0000-0002-7406-5427; John Skoularigis 0000-0001-7159-2478; Andrew Xanthopoulos 0000-0002-9439-3946.

S-Editor: Liu XF

L-Editor: A

P-Editor: Liu XF

REFERENCES

- 1 **Xanthopoulos A**, Giamouzis G, Skoularigis J, Triposkiadis F. Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost? *World J Cardiol* 2022; **14**: 438-445 [PMID: [36161058](#) DOI: [10.4330/wjc.v14.i7.438](#)]
- 2 **Wehner GJ**, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, Kirchner HL, Manus JNA, James N, Ayar Z, Gladding P, Good CW, Cleland JGF, Fornwalt BK. Routinely reported ejection fraction and mortality in clinical practice: Where does the nadir of risk lie? *Eur Heart J* 2020; **41**: 1249-1257 [PMID: [31386109](#) DOI: [10.1093/eurheartj/ehz550](#)]
- 3 **Paulus WJ**, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013; **62**: 263-271 [PMID: [23684677](#) DOI: [10.1016/j.jacc.2013.02.092](#)]
- 4 **Triposkiadis F**, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, Bauersachs J, Burkhardt D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lund IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parissis J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW. The continuous heart failure spectrum: Moving beyond an ejection fraction classification. *Eur Heart J* 2019; **40**: 2155-2163 [PMID: [30957868](#) DOI: [10.1093/eurheartj/ehz158](#)]
- 5 **De Keulenaer GW**, Brutsaert DL. The heart failure spectrum: time for a phenotype-oriented approach. *Circulation* 2009; **119**: 3044-3046 [PMID: [19506105](#) DOI: [10.1161/CIRCULATIONAHA.109.870006](#)]
- 6 **Lupón J**, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, López-Ayerbe J, Domingo M, Núñez J, Zamora E, Moliner P, Santiago-Vacas E, Santesmases J, Bayés-Genis A. Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors. *Circ Heart Fail* 2019; **12**: e005652 [PMID: [30827137](#) DOI: [10.1161/CIRCHEARTFAILURE.118.005652](#)]
- 7 **Heidenreich PA**, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2022; **79**: e263-e421 [PMID: [35379503](#) DOI: [10.1016/j.jacc.2021.12.012](#)]
- 8 **Rezende PC**, Scudeler TL, da Costa LM, Hueb W. Conservative strategy for treatment of stable coronary artery disease. *World J Clin Cases* 2015; **3**: 163-170 [PMID: [25685763](#) DOI: [10.12998/wjcc.v3.i2.163](#)]
- 9 **Zhang JF**, Du YH, Hu HY, Han XQ. Ultrasonographic assessment of cardiac function and disease severity in coronary heart disease. *World J Clin Cases* 2021; **9**: 8366-8373 [PMID: [34754846](#) DOI: [10.12998/wjcc.v9.i28.8366](#)]
- 10 **Anker SD**, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiere-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med* 2021; **385**: 1451-1461 [PMID: [34449189](#) DOI: [10.1056/NEJMoa2107038](#)]
- 11 **Unterhuber M**, Rommel K-P, Kresoja K-P, Lurz J, Kornej J, Hindricks G, Scholz M, Thiele H, Lurz P. Deep learning detects heart failure with preserved ejection fraction using a baseline electrocardiogram. *Eur Heart J - Digital Health* 2021; **2**: 699-703 [DOI: [10.1093/ehjdh/ztab081](#)]
- 12 **Segar MW**, Patel KV, Ayers C, Basit M, Tang WHW, Willett D, Berry J, Grodin JL, Pandey A. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. *Eur J Heart Fail* 2020; **22**: 148-158 [PMID: [31637815](#) DOI: [10.1002/ehf.1621](#)]
- 13 **Woolley RJ**, Ceelen D, Ouwerkerk W, Tromp J, Figarska SM, Anker SD, Dickstein K, Filippatos G, Zannad F, Metra M, Ng L, Samani N, van Veldhuisen DJ, Lang C, Lam CS, Voors AA. Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. *Eur J Heart Fail* 2021; **23**: 983-991 [PMID: [33651430](#) DOI: [10.1002/ehf.2144](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

